Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03190239 | Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients(XQonc-007) | withdrawn | Phase 2 | 0 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05703555 | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701(INTRUSION) | withdrawn | Phase 2 | 0 | Erasmus Medical CenterOTHER | 1 | Feb 28, 2024 |
| clinicaltrials |
| NCT04845035 | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT06018116 | A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.(CANUCK-01) | withdrawn | Phase 2 | 0 | CHU de Quebec-Universite LavalOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT05829434 | Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS(MAGROLIC) | withdrawn | Phase 2 | 0 | Uwe PlatzbeckerOTHER | 0 | Feb 12, 2024 | clinicaltrials |
| NCT04242329 | Surgery of Melanoma Metastases After Systemic Therapy(SUMMIST) | withdrawn | Phase 2 | 0 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT05331131 | Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial | withdrawn | Phase 2 | 0 | Northwell HealthOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT05315687 | Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT05724849 | Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | Vanderbilt University Medical CenterOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 12, 2024 | clinicaltrials |
| NCT03135652 | Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation | withdrawn | Phase 2 | 0 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT03193814 | Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer(XHZL) | withdrawn | Phase 2 | 0 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT00979693 | Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma | withdrawn | Phase 2 | 0 | Multidisciplinary Association for Psychedelic StudiesOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06180863 | Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT02531854 | A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy | withdrawn | Phase 2 | 0 | Advaxis, Inc.INDUSTRY | 0 | Dec 19, 2023 | clinicaltrials |
| NCT04151563 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy(CheckMate 79X) | withdrawn | Phase 1 / Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 19, 2023 | clinicaltrials |
| NCT05948462 | Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib(NSCLC) | withdrawn | Phase 2 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Naoyuki G. Saito, M.D., Ph.D.OTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT04629209 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03735589 | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05998941 | A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer | withdrawn | Phase 2 | 0 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04864522 | Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma(MM FPBMC) | withdrawn | Phase 1 / Phase 2 | 0 | University of VirginiaOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02143050 | Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients | withdrawn | Phase 1 / Phase 2 | 0 | University of LouisvilleOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02432417 | The Addition of Chloroquine to Chemoradiation for Glioblastoma, | withdrawn | Phase 2 | 0 | Maastricht Radiation OncologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT05647512 | Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases | withdrawn | Phase 1 / Phase 2 | 0 | LaNova Medicines LimitedINDUSTRY | 0 | Nov 18, 2023 | clinicaltrials |
| NCT05321862 | Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.(PENTI-MIDAS) | withdrawn | Phase 2 | 0 | Nantes University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02232646 | A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies | withdrawn | Phase 2 | 0 | Sumitomo Pharma America, Inc.INDUSTRY | 0 | Nov 14, 2023 | clinicaltrials |
| NCT05929716 | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 13, 2023 | clinicaltrials |
| NCT06050954 | A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)(CARMA) | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 0 | Nov 9, 2023 | clinicaltrials |
| NCT04684979 | Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies | withdrawn | Phase 2 | 0 | Baptist Health South FloridaOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT05222438 | Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant | withdrawn | Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT05120622 | Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer(Rideau) | withdrawn | Phase 1 / Phase 2 | 0 | University of British ColumbiaOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04648189 | Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC | withdrawn | Phase 2 | 0 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05161533 | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05180422 | A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | withdrawn | Phase 1 / Phase 2 | 0 | Criterium, Inc.INDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT04629651 | Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04265274 | Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer. | withdrawn | Phase 2 | 0 | National Cancer Institute, SlovakiaOTHER_GOV | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05092750 | Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 28, 2023 | clinicaltrials |
| NCT03701321 | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT04989283 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03803761 | A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2023 | clinicaltrials |
| NCT02716688 | S-1 and Radiotherapy for Elderly Esophageal Cancer Patients | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05371860 | Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response | withdrawn | Phase 2 | 0 | Armando GiulianoOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02535988 | Abscopal Effect for Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 0 | Sep 21, 2023 | clinicaltrials |
| NCT03991104 | SOX-based CRT for Esophageal Cancer. | withdrawn | Phase 1 / Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 28, 2024source: clinicaltrials